Teva stock recovered Wednesday on surprisingly light guidance for 2026 following a decisive fourth-quarter beat.

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

Background: Medication adherence is crucial in managing chronic conditions, yet only 50% of chronically ill patients take medications as prescribed, leading to poor health outcomes. Mobile ...

Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and specialty medications. ANIP’s operations are split between rare disease ...

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. Now with its innovative drug franchise ...

-- Product: All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) with the lot numbers noted below. -- Issue: Health products -- Product quality -- What ...

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s ...